Thus, PAP-I mediates the neuron-microglial crosstalk after peripheral nerve injury, and contributes to the maintenance of neuropathic pain.<b>SIGNIFICANCE STATEMENT</b>Neuropathic pain is maladaptive pain condition and the maintaining mechanism is largely unclear.
It can be concluded that the benzylamine derivative of phencyclidine with a methyl group on benzyl position on phenyl ring (V) is more appropriate candidate to reduce acute and chronic (thermal and chemical) pains compared to other substituted phenyl analogs (II-IV) and PCP.
The ≥30% early pain reduction subgroup (n=93) had significantly greater improvements in pain, QOL, and PGI-I and higher ≥30% and ≥50% response rates than placebo; the 10%-30% (n=45) and the <10% (n=33) pain reduction subgroups did not show the same (except 10%-30% group: PGI-I at Week 10 and some QOL at Weeks 10 and/or 14).
The level of pain for the past 7 days was strongly correlated with patient global impression of severity (PGI-S; r = 0.651, p < 0.001) and patient global impression of bother (PGI-B; r = 0.628, p < 0.001).
A PNS system specifically designed for peripheral placement (Neurimpulse, Padova, Italy) was implanted and followed for six months, recording the degree of patient's satisfaction (PGI-I questionnaire), the pain numerical rating scale (NRS) and the quality of life (SF36 questionnaire), as well as any change in drug regimen and work capability.